Table 3.

Impaired proliferation of purified bystander LCMV carrier host T cells from Thy 1.2+ LCMV carrier mice adoptively reconstituted with LCMV-immune Thy 1.1+ splenocytesa

ExptbReconstitution of carrier miceHost cell103 Host cell cpm ± SD
1NoneThy 1.2+ 123 ± 18
LCMV-immune cellsThy 1.2+ 54 ± 5.9
2NoneThy 1.2+ 56 ± 3.9
LCMV-immune cellsThy 1.2+ 35 ± 5.9
3Naive cellsThy 1.2+ 158 ± 9.1
LCMV-immune cellsThy 1.2+ 113 ± 6.1
4Naive cellsThy 1.2+ 127 ± 7.8
LCMV-immune cellsThy 1.2+ 53 ± 8.9
Naive cellsCD8+ Thy 1.2+ 98 ± 3.4
LCMV-immune cellsCD8+ Thy 1.2+ 36 ± 14
5Naive cellsThy 1.2+ 98 ± 16
LCMV-immune cellsThy 1.2+ 54 ± 9.8
Naive cellsCD8+ Thy 1.2+ 62 ± 10
LCMV-immune cellsCD8+ Thy 1.2+ 34 ± 12
  • a Spleen leukocytes from LCMV carrier Thy 1.2+ C57BL/6 mice, either untreated or reconstituted with naive or LCMV-immune Thy 1.1+ C57BL/6 spleen leukocytes, were purified by flow cytometry, stimulated with anti-CD3 antibody, and examined for proliferation by the uptake of [3H]thymidine.

  • b Experiments 1 and 2 used the method described in Materials and Methods. Experiments 3 to 5 used a slightly different method, in which 105 responder cells from the treated mice were placed into 96-well flat-bottom microtiter plates along with 6 × 105 spleen leukocytes from control C57BL/6 mice depleted of T cells with anti-Thy 1.2 and complement, as feeder/accessory cells. [3H]thymidine was added directly to those wells after 2 days of stimulation.